135 related articles for article (PubMed ID: 33189573)
1. Processing laboratory considerations for multi-center cellular therapy clinical trials: a report from the Consortium for Pediatric Cellular Immunotherapy.
Lindgren C; Leinbach A; Annis J; Tanna J; Zhang N; Esensten JH; Hanley PJ
Cytotherapy; 2021 Feb; 23(2):157-164. PubMed ID: 33189573
[TBL] [Abstract][Full Text] [Related]
2. Healthcare center-based cell therapy laboratories supporting off-site manufactured cell therapies: The experiences of a single academic cell therapy laboratory.
Dinh A; Stroncek DF
Transfusion; 2024 Feb; 64(2):357-366. PubMed ID: 38173340
[TBL] [Abstract][Full Text] [Related]
3. Development of a Safety Surveillance Plan for the Academic Medicine Sponsor Performing First-in-Human Cellular Therapy Clinical Trials: A Report from the Consortium for Pediatric Cellular Immunotherapy.
Adams C; Keller M; Michlitsch JG; Aguayo-Hiraldo P; Chen K; Hossain MZ; Davis A; Park JR; Verneris MR; Gardner RA
Transplant Cell Ther; 2024 May; 30(5):475-487. PubMed ID: 38447751
[TBL] [Abstract][Full Text] [Related]
4. Impact of contracted manufacturing organization protocols on operations in an aca demically based Current Good Manufacturing Practice facility.
Sutherland V; Buffo MJ; Whiteside TL
Cytotherapy; 2022 Jan; 24(1):32-36. PubMed ID: 33610480
[TBL] [Abstract][Full Text] [Related]
5. Alignment of practices for data harmonization across multi-center cell therapy trials: a report from the Consortium for Pediatric Cellular Immunotherapy.
Abdel-Azim H; Dave H; Jordan K; Rawlings-Rhea S; Luong A; Wilson AL
Cytotherapy; 2022 Feb; 24(2):193-204. PubMed ID: 34711500
[TBL] [Abstract][Full Text] [Related]
6. The need for uniform and coordinated practices involving centrally manufactured cell therapies.
Stroncek D; Dinh A; Rai H; Zhang N; Somerville R; Panch S
J Transl Med; 2022 Apr; 20(1):184. PubMed ID: 35468789
[TBL] [Abstract][Full Text] [Related]
7. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
Tyagarajan S; Schmitt D; Acker C; Rutjens E
Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
[TBL] [Abstract][Full Text] [Related]
8. Expanding the reach of commercial cell therapies requires changes at medical centers.
Stroncek DF; Zhang N; Ren J; Somerville R; Dinh A
J Transl Med; 2024 Feb; 22(1):181. PubMed ID: 38374090
[TBL] [Abstract][Full Text] [Related]
9. How do I structure logistic processes in preparation for outsourcing of cellular therapy manufacturing?
Chen LN; Collins-Johnson N; Sapp N; Pickett A; West K; Stroncek DF; Panch SR
Transfusion; 2019 Aug; 59(8):2506-2518. PubMed ID: 31135995
[TBL] [Abstract][Full Text] [Related]
10. Proceedings of the first academic symposium on developing, qualifying and operating a cell and gene therapy manufacturing facility.
Digiusto DL; Melsop K; Srivastava R; Tran CT
Cytotherapy; 2018 Dec; 20(12):1486-1494. PubMed ID: 30377039
[TBL] [Abstract][Full Text] [Related]
11. How we manage clinical trials in the cellular therapy laboratory.
Tanhehco YC; Schwartz J
Transfusion; 2018 Jan; 58(1):8-15. PubMed ID: 28940293
[No Abstract] [Full Text] [Related]
12. Point-of-care cell therapy manufacturing; it's not for everyone.
Stroncek DF; Somerville RPT; Highfill SL
J Transl Med; 2022 Jan; 20(1):34. PubMed ID: 35033098
[TBL] [Abstract][Full Text] [Related]
13. Accommodating clinical trials and other externally manufactured cellular therapy products: challenges, lessons learned and creative solutions.
Jackson MR
Cytotherapy; 2022 Jan; 24(1):37-44. PubMed ID: 34305008
[TBL] [Abstract][Full Text] [Related]
14. Benefits of a comprehensive quality program for cryopreserved PBMC covering 28 clinical trials sites utilizing an integrated, analytical web-based portal.
Ducar C; Smith D; Pinzon C; Stirewalt M; Cooper C; McElrath MJ; Hural J;
J Immunol Methods; 2014 Jul; 409():9-20. PubMed ID: 24709391
[TBL] [Abstract][Full Text] [Related]
15. Variations in novel cellular therapy products manufacturing.
Fontaine MJ; Selogie E; Stroncek D; McKenna D; Szczepiorkowski ZM; Takanashi M; Garritsen H; Girdlestone J; Reems JA;
Cytotherapy; 2020 Jun; 22(6):337-342. PubMed ID: 32223996
[TBL] [Abstract][Full Text] [Related]
16. Place of Academic GMP Facilities in Modern Cell Therapy.
Bersenev A; Fesnak A
Methods Mol Biol; 2020; 2097():329-339. PubMed ID: 31776936
[TBL] [Abstract][Full Text] [Related]
17. Compliance and cost control for cryopreservation of cellular starting materials: An industry perspective.
Adriaansen J; Stanton J; Schaut W; Bowden R
Cytotherapy; 2022 Jul; 24(7):750-753. PubMed ID: 35304076
[TBL] [Abstract][Full Text] [Related]
18. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
19. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.
Ten Ham RMT; Hövels AM; Hoekman J; Frederix GWJ; Leufkens HGM; Klungel OH; Jedema I; Veld SAJ; Nikolic T; Van Pel M; Zwaginga JJ; Lin F; de Goede AL; Schreibelt G; Budde S; de Vries IJM; Wilkie GM; Dolstra H; Ovelgönne H; Meij P; Mountford JC; Turner ML; Hoefnagel MHN
Cytotherapy; 2020 Jul; 22(7):388-397. PubMed ID: 32414635
[TBL] [Abstract][Full Text] [Related]
20. Training practices of cell processing laboratory staff: analysis of a survey by the Alliance for Harmonization of Cellular Therapy Accreditation.
Keever-Taylor CA; Slaper-Cortenbach I; Celluzzi C; Loper K; Aljurf M; Schwartz J; Mcgrath E; Eldridge P;
Cytotherapy; 2015 Dec; 17(12):1831-44. PubMed ID: 26455277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
